OR WAIT null SECS
November 24, 2025
Moderna secures a $1.5 billion loan to enhance financial flexibility while targeting a 10% revenue growth by 2026, focusing on innovative mRNA therapies.
Abbott's deal shakes up cancer diagnostics, new research confirms pandemic fatigue's impact on public compliance, and more in today’s Pharma Pulse.
November 21, 2025
While studies reveal the complex, varying, and long-lasting burden of Long COVID symptoms, biopharma giants Novartis and Moderna commit significant capital to new facilities, reinforcing US drug supply resilience in today’s Pharma Pulse.
November 20, 2025
As part of its multi-billion-dollar investment, the company will be creating a unified, end-to-end manufacturing campus spanning biologics, gene therapy, solid dosage, and packaging operations.
November 19, 2025
A US-China Economic and Security Review Commission report highlights China’s tightening grip on APIs, biomanufacturing, and R&D services, raising alarms about supply chain vulnerabilities, data transparency gaps, and the urgent need for US policy action.
November 18, 2025
The company is launching new self-pay pricing options, expanded savings programs, and partnerships with telehealth and retail providers. all while its obesity portfolio gains momentum under the FDA’s National Priority Voucher program.
November 17, 2025
This episode of Pharma Pulse discusses how new analysis shows poor treatment and monitoring rates among young adults with high cholesterol, while national efforts ramp up to identify pharmacy deserts—and one US pharmacy becomes the first to accept cryptocurrency for prescriptions.
November 14, 2025
The nationally licensed pharmacy network now supports Ethereum, Solana, and XRP across all retail locations, marking a major step toward faster, more transparent payments—and laying the groundwork for a blockchain-based prescription drug payment system.
This episode of Pharma Pulse discusses how the FDA’s new plausible mechanism pathway, WeightWatchers’ plans to offer oral Wegovy, and emerging evidence on berberine are shaping the future of obesity and metabolic health care.
November 13, 2025
This episode of Pharma Pulse discusses how Dr. Richard Pazdur’s appointment signals a new era for FDA drug evaluation, why hospitals are opposing the government’s 340B pilot program, and how Novartis is expanding its US manufacturing footprint with a new radioligand therapy facility in California.